Global record of patients with anal squamous cell carcinoma and HIV
ACTION HIV (Anal Cancer TherapIes and Outcomes iNitiative for Patients Living With and Without HIV): A Global Record of Patients With Anal Squamous Cell Carcinoma With and Without HIV Infection
This study is gathering information from patients with anal squamous cell carcinoma, both with and without HIV, to see how different factors affect their treatment and outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Latin American Cooperative Oncology Group Academic / other |
| Locations | 1 site (São Paulo) |
| Trial ID | NCT05328765 on ClinicalTrials.gov |
What this trial studies
This observational study aims to gather comprehensive data on patients diagnosed with anal squamous cell carcinoma (ASCC), both with and without HIV infection, from various regions around the world. It will evaluate prognostic factors such as CD4 counts, duration of HIV infection, viral load, and clinical staging, as well as treatment modalities and comorbidities. By analyzing these factors, the study seeks to enhance understanding of the disease's progression and treatment outcomes in diverse populations.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with a confirmed diagnosis of anal squamous cell carcinoma and a serological test for HIV.
Not a fit: Patients who lack sufficient data on their treatments and clinical outcomes will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights that improve treatment strategies and outcomes for patients with anal squamous cell carcinoma, particularly those co-infected with HIV.
How similar studies have performed: While there is limited data on similar studies, the approach of evaluating prognostic factors in a global context is relatively novel and could provide new insights into the management of anal squamous cell carcinoma.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients 18 years of age or older * Confirmed histological diagnosis of anal canal squamous cell carcinoma. Basaloid subtype is accepted * Have underundered serological test for HIV infection * Any clinical stage Exclusion Criteria: * Lack of data on treatments and clinical outcomes
Where this trial is running
São Paulo
- A.C. Camargo Cancer Center — São Paulo, Brazil (Recruiting)
Study contacts
- Principal investigator: Rachel Riechelmann — Brazilian Group of Gastrointestinal Tumors
- Study coordinator: Viviane Horn de Melo
- Email: viviane.melo@lacogcancerresearch.org
- Phone: +55 51 3384 5334
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.